Steric Blockade of Oxy-Myoglobin Oxidation by Thiosemicarbazones: Structure–Activity Relationships of the Novel PPP4pT Series
出版年份 2023 全文链接
标题
Steric Blockade of Oxy-Myoglobin Oxidation by Thiosemicarbazones: Structure–Activity Relationships of the Novel PPP4pT Series
作者
关键词
-
出版物
JOURNAL OF MEDICINAL CHEMISTRY
Volume -, Issue -, Pages -
出版商
American Chemical Society (ACS)
发表日期
2023-11-04
DOI
10.1021/acs.jmedchem.3c01612
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Designing Tailored Thiosemicarbazones with Bespoke Properties: The Styrene Moiety Imparts Potent Activity, Inhibits Heme Center Oxidation, and Results in a Novel “Stealth Zinc(II) Complex”
- (2023) Mahendiran Dharmasivam et al. Journal of Medicinal Chemistry
- Dual Role of Glutathione as a Reducing Agent and Cu-Ligand Governs the ROS Production by Anticancer Cu-Thiosemicarbazone Complexes
- (2023) Alessandra G. Ritacca et al. Inorganic Chemistry
- “Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery
- (2023) Debora Chiodi et al. Journal of Medicinal Chemistry
- Developing a Multitargeted Anticancer Palladium(II) Agent Based on the His-242 Residue in the IIA Subdomain of Human Serum Albumin
- (2023) Wenjuan Li et al. Journal of Medicinal Chemistry
- Developing a Gadolinium(III) Compound Based on Apoferritin for Targeted Magnetic Resonance Imaging and Dual-Modal Therapy of Cancer
- (2023) Xueyu Man et al. Journal of Medicinal Chemistry
- The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics
- (2023) Zhao Deng et al. PHARMACOLOGICAL REVIEWS
- Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer
- (2023) Faten Shehadeh-Tout et al. PHARMACOLOGICAL RESEARCH
- Aqueous Iron(IV)–Oxo Complex: An Emerging Powerful Reactive Oxidant Formed by Iron(II)-Based Advanced Oxidation Processes for Oxidative Water Treatment
- (2022) Zhen Wang et al. ENVIRONMENTAL SCIENCE & TECHNOLOGY
- Discovery of new PKN2 inhibitory chemotypes via QSAR-guided selection of docking-based pharmacophores
- (2022) Mahmoud A. Al-Sha’er et al. MOLECULAR DIVERSITY
- The thiosemicarbazone, DpC, broadly synergizes with multiple anti-cancer therapeutics and demonstrates temperature- and energy-dependent uptake by tumor cells
- (2022) Mahendiran Dharmasivam et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Copper-Catalyzed Glutathione Oxidation is Accelerated by the Anticancer Thiosemicarbazone Dp44mT and Further Boosted at Lower pH
- (2022) Enrico Falcone et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- An efficient ultrasound-assisted CH3COONa catalyzed synthesis of thiazolidinone molecule: Theoretical and nonlinear optical evaluations of thiazolidinone-Schiff base derivative
- (2022) Jinan Khudhair Salim et al. OPTICAL MATERIALS
- Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
- (2022) Michael J. Duffy et al. Cancers
- Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance
- (2022) Vivien Pósa et al. Cancers
- Breaking the cycle: Targeting of NDRG1 to inhibit bi‐directional oncogenic cross‐talk between pancreatic cancer and stroma
- (2021) Bekesho Geleta et al. FASEB JOURNAL
- Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53
- (2021) John A. Gilleran et al. JOURNAL OF MEDICINAL CHEMISTRY
- Innovative Therapies for Neuroblastoma: The Surprisingly Potent Role of Iron Chelation in Up-Regulating Metastasis and Tumor Suppressors and Down-Regulating the Key Oncogene, N-myc
- (2021) Tharushi P. Wijesinghe et al. PHARMACOLOGICAL RESEARCH
- The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity
- (2021) Jason Chekmarev et al. Cells
- Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Fluorinated Candidates as PI3K Inhibitors: Targeting Fluorophilic Binding Sites
- (2021) Ahmed H. Tantawy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis, In Silico Study, and Anti-Cancer Activity of Thiosemicarbazone Derivatives
- (2021) Belay Zeleke Sibuh et al. Biomedicines
- Unique targeting of androgen‐dependent and ‐independent AR signaling in prostate cancer to overcome androgen resistance
- (2020) Syer C. Lim et al. FASEB JOURNAL
- Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux
- (2020) Julia H. Bormio Nunes et al. JOURNAL OF MEDICINAL CHEMISTRY
- COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms
- (2019) Antje Lindemann et al. CLINICAL CANCER RESEARCH
- Synthetic approaches and pharmaceutical applications of chloro-containing molecules for drug discovery: A critical review
- (2019) Wan-Yin Fang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PEG-conjugated triacontanol micelles as docetaxel delivery systems for enhanced anti-cancer efficacy
- (2019) Xiaoyu Lu et al. Drug Delivery and Translational Research
- Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers
- (2019) Charles A. Kunos et al. Frontiers in Oncology
- Autodock Vina Adopts More Accurate Binding Poses but Autodock4 Forms Better Binding Affinity
- (2019) Nguyen Thanh Nguyen et al. Journal of Chemical Information and Modeling
- Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development
- (2018) Petra Heffeter et al. ANTIOXIDANTS & REDOX SIGNALING
- Investigation of the Redox and Acid-Base properties of TCNQF and TCNQF2 : Electrochemistry, Vibrational Spectroscopy, and Substituent Effects
- (2018) Nguyen Vo et al. ChemElectroChem
- Abstract CT033: Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer
- (2018) Shannon N. Westin et al. CANCER RESEARCH
- Effect of Inflammatory Mediators Lipopolysaccharide and Lipoteichoic Acid on Iron Metabolism of Differentiated SH-SY5Y Cells Alters in the Presence of BV-2 Microglia
- (2018) Edina Pandur et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma
- (2017) Marco Lodrini et al. Oncotarget
- Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies
- (2016) Charles A. Kunos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K/AKT/mTOR pathway
- (2016) K.Y. Salim et al. EUROPEAN JOURNAL OF CANCER
- The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms
- (2016) Zhu-Ling Guo et al. Journal of Hematology & Oncology
- Kinetico-mechanistic studies on methemoglobin generation by biologically active thiosemicarbazone iron(III) complexes
- (2016) Maram T. Basha et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Zinc(II)–Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity
- (2016) Alexandra E. Stacy et al. JOURNAL OF MEDICINAL CHEMISTRY
- A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC
- (2016) Nicole A Seebacher et al. Cell Death & Disease
- COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
- (2016) Kowthar Y. Salim et al. Oncotarget
- Nano-curcumin prepared via supercritical: Improved anti-bacterial, anti-oxidant and anti-cancer efficacy
- (2015) Maobin Xie et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug Resistance by a Novel Mechanism Involving the Hijacking of Lysosomal P-Glycoprotein (Pgp)
- (2015) Patric J. Jansson et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter
- (2015) Nicole A. Seebacher et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Novel Mechanism of Cytotoxicity for the Selective Selenosemicarbazone, 2-Acetylpyridine 4,4-Dimethyl-3-selenosemicarbazone (Ap44mSe): Lysosomal Membrane Permeabilization
- (2015) Zaynab Al-Eisawi et al. JOURNAL OF MEDICINAL CHEMISTRY
- The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the “Triad of Death” in cancer by Di-2-pyridylketone thiosemicarbazones
- (2015) Patric J. Jansson et al. PHARMACOLOGICAL RESEARCH
- Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
- (2015) Vit Sestak et al. Oncotarget
- Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties
- (2014) Silvia Serra et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of -catenin through mechanisms involving FRAT1 and PAK4
- (2014) R. Jin et al. JOURNAL OF CELL SCIENCE
- Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia
- (2013) Maram T. Basha et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
- (2012) Christopher A. Lipinski et al. ADVANCED DRUG DELIVERY REVIEWS
- Novel Chelators for Cancer Treatment: Where Are We Now?
- (2012) Angelica M. Merlot et al. ANTIOXIDANTS & REDOX SIGNALING
- Design of iron chelators with therapeutic application
- (2012) Tao Zhou et al. DALTON TRANSACTIONS
- N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis
- (2012) Wen Liu et al. EMBO Molecular Medicine
- The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)
- (2012) Zhiqiang Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo
- (2012) David B. Lovejoy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Simple pyrazoline and pyrazole “turn on” fluorescent sensors selective for Cd2+ and Zn2+ in MeCN
- (2012) Alexander Ciupa et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Evidence of asymmetric cell division and centrosome inheritance in human neuroblastoma cells
- (2012) H. Izumi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy
- (2011) Y Yu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes
- (2011) D. B. Lovejoy et al. CANCER RESEARCH
- What has polar surface area ever done for drug discovery?
- (2011) David E Clark Future Medicinal Chemistry
- Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer
- (2011) Z. Kovacevic et al. MOLECULAR PHARMACOLOGY
- Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity
- (2010) Patric J. Jansson et al. JOURNAL OF MEDICINAL CHEMISTRY
- A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
- (2009) Anne M. Traynor et al. INVESTIGATIONAL NEW DRUGS
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
- (2009) Garrett M. Morris et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- 2-Acetylpyridine Thiosemicarbazones are Potent Iron Chelators and Antiproliferative Agents: Redox Activity, Iron Complexation and Characterization of their Antitumor Activity
- (2009) Des R. Richardson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells
- (2008) Egarit Noulsri et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents
- (2008) D.R. Richardson et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Iron Chelators of the Dipyridylketone Thiosemicarbazone Class: Precomplexation and Transmetalation Effects on Anticancer Activity
- (2008) Paul V. Bernhardt et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Cytosolic Iron Chaperone That Delivers Iron to Ferritin
- (2008) H. Shi et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started